We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+6.38%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.96B
AUM Growth
+$853M
(+12%)
Cap. Flow
+$1.08B
Cap. Flow
% of AUM
13.6%
Top 10 Holdings %
Top 10 Hldgs %
33.59%
Holding
163
New
28
Increased
23
Reduced
24
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Prelude Therapeutics
PRLD
|
+$440M |
| 2 |
PMV Pharmaceuticals
PMVP
|
+$270M |
| 3 |
AFIB
Acutus Medical Inc
AFIB
|
+$166M |
| 4 |
Adicet Bio
ACET
|
+$95.1M |
| 5 |
Theravance Biopharma
TBPH
|
+$68.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$119M |
| 2 |
Cigna
CI
|
+$82.5M |
| 3 |
Natera
NTRA
|
+$64.2M |
| 4 |
Alector
ALEC
|
+$52.6M |
| 5 |
Glaukos
GKOS
|
+$46.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.96% |
| 2 | Financials | 0.63% |
| 3 | Technology | 0.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IGMS
151
DELISTED
IGM Biosciences
IGMS
| – | – |
-80,760
| Closed | -$5.89M |
|
152
Immunovant
IMVT
$7.84B
| – | – |
-354,575
| Closed | -$8.63M |
|
153
Inspire Medical Systems
INSP
$1.5B
| – | – |
-347,000
| Closed | -$30.2M |
|
154
IQVIA
IQV
$40.6B
| – | – |
-175,000
| Closed | -$24.8M |
|
155
Intellia Therapeutics
NTLA
$1.49B
| – | – |
-137,100
| Closed | -$2.88M |
|
156
Arcus Biosciences
RCUS
$3.36B
| – | – |
-220,350
| Closed | -$5.45M |
|
157
Regeneron Pharmaceuticals
REGN
$73.2B
| – | – |
-30,900
| Closed | -$19.3M |
|
158
SelectQuote
SLQT
$130M
| – | – |
-1,255,000
| Closed | -$31.8M |
|
159
10x Genomics
TXG
$5.92B
| – | – |
-92,700
| Closed | -$8.28M |
|
160
VYNE Therapeutics
VYNE
| – | – |
-165
| Closed | -$1.03M |
|
|
GNMK
161
DELISTED
GenMark Diagnostics, Inc
GNMK
| – | – |
-732,000
| Closed | -$10.8M |
|
|
IMMU
162
DELISTED
Immunomedics Inc
IMMU
| – | – |
-757,900
| Closed | -$26.9M |
|
|
BFYT
163
DELISTED
Benefytt Technologies, Inc. Class A Common Stock
BFYT
| – | – |
-962,900
| Closed | -$19.7M |
|
Similar funds
HSA
LIM
NL
BPWM
LFG
JIM
CTC
PAMP
OrbiMed's Q3 2020 Portfolio in Review
As of Q3 2020, OrbiMed held 163 positions worth $7.96B, up 12% from $7.1B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
OrbiMed deployed $1.08B of net new capital in Q3 2020, opening 28 new positions and adding to 23 existing holdings. Its largest new stake was Prelude Therapeutics: 15,594,877 shares worth $470M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $119M trimmed.
- OrbiMed's largest Q3 2020 buy was Prelude Therapeutics: 15,594,877 shares worth $470M.
- OrbiMed added most to Adicet Bio in Q3 2020, an estimated $95.1M increase.
- OrbiMed's biggest Q3 2020 reduction was Ascendis Pharma A/S, cutting an estimated $119M.
- OrbiMed fully exited Cigna in Q3 2020, selling an estimated $82.5M.
- OrbiMed's ten largest holdings make up 34% of its $7.96B portfolio in Q3 2020.
- OrbiMed opened 28 new positions and closed 20 in Q3 2020.
- OrbiMed's portfolio value rose 12% quarter-over-quarter to $7.96B.
Based on OrbiMed's 13F filing for Q3 2020, filed 16 Nov 2020.